Clinical trials during post-COVID pandemic: An interim review / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
; (12): 591-594, 2020.
Article
en Zh
| WPRIM
| ID: wpr-855843
Biblioteca responsable:
WPRO
ABSTRACT
China has experienced an unprecedented pandemic of corona virus disease 2019 (COVID-19) in 2020. In the background of serious public health events, clinical trials in most Chinese regions have experienced a series of tough periods such as suspension of admission and protocol violation. With resumption of work and production around the country, China has entered the post-COVID pandemic period. This article analyzes how clinical trial institutions resume professional work, and advocates to continue to strengthen the countermeasures and experience during the outbreak, such as the design of subject-centered clinical trial, comprehensively promotion of information technology, construction of professional clinical research centers and clinical research support teams, respecting evidence-based evidence and real-world evidence, optimal ethical committee review modes, and standardization of agency disaster recovery plan. These experiences should be applied to future clinical researches.
Texto completo:
1
Índice:
WPRIM
Tipo de estudio:
Guideline
Idioma:
Zh
Revista:
Chinese Journal of Clinical Pharmacology and Therapeutics
Año:
2020
Tipo del documento:
Article